nach oben

Erschienen in:

01.09.2011 | Original Article

Acute and Chronic Histological Changes of the Small Bowel Secondary to C. jejuni Infection in a Rat Model for Post-Infectious IBS

verfasst von: Walter Morales, Mark Pimentel, Laura Hwang, David Kunkel, Venkata Pokkunuri, Benjamin Basseri, Kimberly Low, Hanlin Wang, Jeffrey L. Conklin, Christopher Chang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Campylobacter jejuni has been implicated in the pathogenesis of post-infectious irritable bowel syndrome (PI-IBS) in humans, effects which may be because of cytolethal distending toxin (CDT). In this study, we characterized both acute and chronic-phase histological changes of the small bowel in rats exposed to wild-type C. jejuni 81-176, or a strain that does not produce CDT, by using a validated rat model of PI-IBS.

Methods

Sprague–Dawley rats were given 1.0 × 10⁸ CFU of either wild-type C. jejuni 81-176 (C+, PI/C+) or the CDT-negative strain (CDT−), or vehicle alone (Control). Acute-phase rats (C+, CDT−) were euthanized on days 2, 4, 8, 16, and 32. Chronic-phase rats (PI/C+, Control) were euthanized 3 months after clearing the initial infection. Segments of duodenum, jejunum, and ileum were resected and the contents plated for C. jejuni culture, and tissue sections were stained for histology.

Results

We observed preferential infection of the ileum and jejunum by Campylobacter jejuni. Compared with controls, epithelial cell basal membrane ballooning, villous tip disruption, and reduced villous-to-crypt ratios were observed for both C+ and CDT− rats. Villous widening, the only result significantly different in C+ vs. CDT− rats, was greatest at day 4 (134.1 ± 21.12 μm vs. 109.9 ± 10.6 μm for CDT−, P < 0.01). Little or no cellular inflammatory changes were seen during acute C. jejuni infection. Three months after clearing the initial infection, no histological changes remained.

Conclusion

Significant histological changes, with the absence of inflammatory cells, are seen in the duodenum, jejunum, and ileum of rats during acute infection with C. jejuni. These changes occurred irrespective of the presence or absence of the CDT toxin.

Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (ibs) and variability of diagnostic criteria. Gastroenterol Clin Biol. 2004;28:554–561.PubMedCrossRef

El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3:S3–11.PubMed

Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–680.PubMedCrossRef

Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314:779–782.PubMed

Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case–control study. Am J Gastroenterol. 2003;98:327–331.PubMedCrossRef

Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut. 2002;51:410–413.PubMedCrossRef

Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis. 2001;184:606–609.PubMedCrossRef

Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774–1778.PubMedCrossRef

Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98–104.PubMedCrossRef

10.

Johnson WM, Lior H. A new heat-labile cytolethal distending toxin (cldt) produced by Campylobacter spp. Microb Pathog. 1988;4:115–126.PubMedCrossRef

11.

Pickett CL, Cottle DL, Pesci EC, Bikah G. Cloning, sequencing, and expression of the escherichia coli cytolethal distending toxin genes. Infect Immun. 1994;62:1046–1051.PubMed

12.

Pickett CL, Pesci EC, Cottle DL, Russell G, Erdem AN, Zeytin H. Prevalence of cytolethal distending toxin production in Campylobacter jejuni and relatedness of Campylobacter sp. Cdtb gene. Infect Immun. 1996;64:2070–2078.PubMed

13.

Scott DA, Kaper JB. Cloning and sequencing of the genes encoding Escherichia coli cytolethal distending toxin. Infect Immun. 1994;62:244–251.PubMed

14.

Haghjoo E, Galan JE. Salmonella typhi encodes a functional cytolethal distending toxin that is delivered into host cells by a bacterial-internalization pathway. Proc Natl Acad Sci USA. 2004;101:4614–4619.PubMedCrossRef

15.

Smith JL, Bayles DO. The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol. 2006;32:227–248.PubMedCrossRef

16.

Heywood W, Henderson B, Nair SP. Cytolethal distending toxin: creating a gap in the cell cycle. J Med Microbiol. 2005;54:207–216.PubMedCrossRef

17.

Lara-Tejero M, Galan JE. Cdta, cdtb, and cdtc form a tripartite complex that is required for cytolethal distending toxin activity. Infect Immun. 2001;69:4358–4365.PubMedCrossRef

18.

Cortes-Bratti X, Frisan T, Thelestam M. The cytolethal distending toxins induce DNA damage and cell cycle arrest. Toxicon. 2001;39:1729–1736.PubMedCrossRef

19.

Lara-Tejero M, Galan JE. Cytolethal distending toxin: limited damage as a strategy to modulate cellular functions. Trends Microbiol. 2002;10:147–152.PubMedCrossRef

20.

Fox JG, Rogers AB, Whary MT, et al. Gastroenteritis in nf-kappab-deficient mice is produced with wild-type Campylobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains. Infect Immun. 2004;72:1116–1125.PubMedCrossRef

21.

Chang C, Miller JF. Campylobacter jejuni colonization of mice with limited enteric flora. Infect Immun. 2006;74:5261–5271.PubMedCrossRef

22.

Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53:982–989.PubMedCrossRef

23.

Dasti JI, Tareen AM, Lugert R, Zautner AE, Gross U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol. 2010;300:205–211.PubMedCrossRef

24.

Tauxe R. Incidence, trends and sources of campylobacteriosis in developed countries: an overview. The increasing incidence of human campylobacteriosis. 2001; 42–43.

25.

Lastovica A, Skirrow M. Clinical significance of campylobacter and related species other than Campylobacter jejuni and C. coli. In: Nachamkin I, Blaser M, eds. Campylobacter. Washington, DC: ASM Press; 2000:89–120.

26.

Blaser MJ, Reller LB. Campylobacter enteritis. N Engl J Med. 1981;305:1444–1452.PubMedCrossRef

27.

Drake AA, Gilchrist MJ, Washington JA 2nd, Huizenga KA, Van Scoy RE. Diarrhea due to Campylobacter fetus subspecies jejuni. A clinical review of 63 cases. Mayo Clin Proc. 1981;56:414–423.PubMed

28.

Karmali MA, Fleming PC. Campylobacter enteritis. Can Med Assoc J. 1979;120:1525–1532.PubMed

29.

Pitkanen T, Ponka A, Pettersson T, Kosunen TU. Campylobacter enteritis in 188 hospitalized patients. Arch Intern Med. 1983;143:215–219.PubMedCrossRef

30.

Robinson DA. Campylobacter infection. R Soc Health J. 1981;101:138–140.PubMedCrossRef

31.

Johnson RJ, Nolan C, Wang SP, Shelton WR, Blaser MJ. Persistent Campylobacter jejuni infection in an immunocompromised patient. Ann Intern Med. 1984;100:832–834.PubMed

32.

Melamed I, Bujanover Y, Igra YS, Schwartz D, Zakuth V, Spirer Z. Campylobacter enteritis in normal and immunodeficient children. Am J Dis Child. 1983;137:752–753.PubMed

33.

Perlman DM, Ampel NM, Schifman RB, et al. Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV). Ann Intern Med. 1988;108:540–546.PubMed

34.

Watson RO, Novik V, Hofreuter D, Lara-Tejero M, Galan JE. A myd88-deficient mouse model reveals a role for nramp1 in Campylobacter jejuni infection. Infect Immun. 2007;75:1994–2003.PubMedCrossRef

35.

Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef

36.

Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, t lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811.PubMedCrossRef

37.

Mansfield LS, Bell JA, Wilson DL, et al. C57bl/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis. Infect Immun. 2007;75:1099–1115.PubMedCrossRef

38.

Pigrau C, Bartolome R, Almirante B, Planes AM, Gavalda J, Pahissa A. Bacteremia due to campylobacter species: clinical findings and antimicrobial susceptibility patterns. Clin Infect Dis. 1997;25:1414–1420.PubMedCrossRef

Titel: Acute and Chronic Histological Changes of the Small Bowel Secondary to C. jejuni Infection in a Rat Model for Post-Infectious IBS
verfasst von: Walter Morales
Mark Pimentel
Laura Hwang
David Kunkel
Venkata Pokkunuri
Benjamin Basseri
Kimberly Low
Hanlin Wang
Jeffrey L. Conklin
Christopher Chang
Publikationsdatum: 01.09.2011
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-011-1662-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Gender Bias in Gastroparesis: Is Nitric Oxide the Answer?

Comparison of Self-Expanding Metal Stents and Urgent Surgery for Left-Sided Malignant Colonic Obstruction in Elderly Patients

Effect of Oral Insulin on Diabetes-Induced Intestinal Mucosal Growth in Rats

Potential Preventability of Spontaneous Bacterial Peritonitis

Recommendations for Post-Polypectomy Surveillance in Community Practice